InsiderTrades.com logo
Milton C. Ault III net worth and biography
  • Phone
  • Website

Milton Ault III Biography and Net Worth

Major Shareholder of Alzamend Neuro
Milton C. (Todd) Ault III founded our company and has served as our Chairman of the Board since inception and as our Executive Chairman since November 2018. As of June 10, 2021, Mr. Ault serves as our Chairman Emeritus. Mr. Ault is a seasoned business professional and entrepreneur who has spent more than 27 years identifying value in various financial markets including equities, fixed income, commodities and real estate. In March 2017, Mr. Ault was appointed Executive Chairman of the Board of Ault Global, in December 2017, Mr. Ault was appointed Chief Executive Officer of Ault Global and, on January 12, 2021, Mr. Ault resumed his title of Executive Chairman. Mr. Ault has served as Chairman of Ault & Company, a holding company since December 2015, and as Chairman of Avalanche International Corp., a publicly traded company (“Avalanche”), since September 2014. Since January 2011, Mr. Ault has been the Vice President of Business Development for MCKEA Holdings, LLC, a family office. Mr. Ault has consulted with many publicly traded and privately held companies, which range from development stage to mature businesses, providing each of them the benefit of his diversified experience.

What is Milton C. Ault III's net worth?

The estimated net worth of Milton C. Ault III is at least $87,310.08 as of March 18th, 2025. Mr. Ault III owns 82,368 shares of Alzamend Neuro stock worth more than $87,310 as of March 31st. This net worth approximation does not reflect any other investments that Mr. Ault III may own. Learn More about Milton C. Ault III's net worth.

How old is Milton C. Ault III?

Mr. Ault III is currently 54 years old. There are 4 older executives and no younger executives at Alzamend Neuro. The oldest executive at Alzamend Neuro is Mr. Kenneth S. Cragun CPA, Senior Vice President of Finance, who is 63 years old. Learn More on Milton C. Ault III's age.

How do I contact Milton C. Ault III?

The corporate mailing address for Mr. Ault III and other Alzamend Neuro executives is , , . Alzamend Neuro can also be reached via phone at 844-722-6303. Learn More on Milton C. Ault III's contact information.

Has Milton C. Ault III been buying or selling shares of Alzamend Neuro?

During the last ninety days, Milton C. Ault III has bought $4,868.00 of Alzamend Neuro stock. Most recently, on Tuesday, March 18th, Milton C. Ault III bought 5,000 shares of Alzamend Neuro stock. The stock was acquired at an average cost of $0.96 per share, with a total value of $4,800.00. Following the completion of the transaction, the director now directly owns 82,368 shares of the company's stock, valued at $79,073.28. Learn More on Milton C. Ault III's trading history.

Who are Alzamend Neuro's active insiders?

Alzamend Neuro's insider roster includes Milton Ault III (Major Shareholder), Milton Ault, III (Major Shareholder), Milton Ault, III. (Major Shareholder), Mark Gustafson (Director), and L. Smith (Insider). Learn More on Alzamend Neuro's active insiders.

Are insiders buying or selling shares of Alzamend Neuro?

During the last year, Alzamend Neuro insiders bought shares 8 times. They purchased a total of 13,667 shares worth more than $14,358.71. The most recent insider tranaction occured on March, 26th when Director William B Horne bought 3,334 shares worth more than $3,300.66. Insiders at Alzamend Neuro own 30.2% of the company. Learn More about insider trades at Alzamend Neuro.

Information on this page was last updated on 3/26/2025.

Milton C. Ault III Insider Trading History at Alzamend Neuro

Milton C. Ault III Buying and Selling Activity at Alzamend Neuro

This chart shows Milton C Ault III's buying and selling at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$4.87kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Alzamend Neuro Company Overview

Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More

Today's Range

Now: $1.06
Low: $1.00
High: $1.10

50 Day Range

MA: $0.99
Low: $0.67
High: $1.19

2 Week Range

Now: $1.06
Low: $0.64
High: $15.06

Volume

148,329 shs

Average Volume

567,484 shs

Market Capitalization

$6.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A